Cargando…

A two-step immunoassay for the simultaneous assessment of Aβ38, Aβ40 and Aβ42 in human blood plasma supports the Aβ42/Aβ40 ratio as a promising biomarker candidate of Alzheimer’s disease

BACKGROUND: The quantification of amyloid-beta (Aβ) peptides in blood plasma as potential biomarkers of Alzheimer’s disease (AD) is hampered by very low Aβ concentrations and the presence of matrix components that may interfere with the measurements. METHODS: We developed a two-step immunoassay for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shahpasand-Kroner, Hedieh, Klafki, Hans-W., Bauer, Chris, Schuchhardt, Johannes, Hüttenrauch, Melanie, Stazi, Martina, Bouter, Caroline, Wirths, Oliver, Vogelgsang, Jonathan, Wiltfang, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286509/ https://www.ncbi.nlm.nih.gov/pubmed/30526652 http://dx.doi.org/10.1186/s13195-018-0448-x

Ejemplares similares

Is plasma amyloid-β 1–42/1–40 a better biomarker for Alzheimer’s disease than AβX–42/X–40?
por: Klafki, Hans-Wolfgang, et al.
Publicado: (2022)

Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
por: Lewczuk, Piotr, et al.
Publicado: (2021)

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Cathepsin D regulates cerebral Aβ42/40 ratios via differential degradation of Aβ42 and Aβ40
por: Suire, Caitlin N., et al.
Publicado: (2020)

CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer’s Disease and Frontotemporal Dementias
por: Constantinides, Vasilios C., et al.
Publicado: (2023)

Development and Technical Validation of an Immunoassay for the Detection of APP(669–711) (Aβ(−3–40)) in Biological Samples
por: Klafki, Hans W., et al.
Publicado: (2020)

Validation of Immunoassay-Based Tools for the Comprehensive Quantification of Aβ(40) and Aβ(42) Peptides in Plasma
por: Pérez-Grijalba, Virginia, et al.
Publicado: (2016)

Combined Analysis of CSF Tau, Aβ42, Aβ1–42% and Aβ1–40(ox)% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia
por: Bibl, Mirko, et al.
Publicado: (2010)

Amyloid-β peptide 37, 38 and 40 individually and cooperatively inhibit amyloid-β 42 aggregation
por: Braun, Gabriel A., et al.
Publicado: (2022)

Aβ(42)/Aβ(40) and Aβ(42)/Aβ(38) Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimer’s Disease: A Pilot Study
por: Koychev, Ivan, et al.
Publicado: (2018)

A novel study on amyloid β peptide 40, 42 and 40/42 ratio in Saudi autistics
por: Al- Ayadhi, Laila Y, et al.
Publicado: (2012)

Tau pathogenesis is promoted by Aβ1-42 but not Aβ1-40
por: Hu, Xiaoyan, et al.
Publicado: (2014)

Different Aggregation Pathways and Structures for Aβ40 and Aβ42 Peptides
por: Wang, Li, et al.
Publicado: (2021)

Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Impact of Aβ40 and Aβ42 Fibrils on the Transcriptome of Primary Astrocytes and Microglia
por: Zhu, Xiaoyue, et al.
Publicado: (2022)

Aggregation States of Aβ(1–40), Aβ(1–42) and Aβp(3–42) Amyloid Beta Peptides: A SANS Study
por: Festa, Giulia, et al.
Publicado: (2019)

Synergistic Effect on Neurodegeneration by N-Truncated Aβ(4−42) and Pyroglutamate Aβ(3−42) in a Mouse Model of Alzheimer's Disease
por: Lopez-Noguerola, Jose S., et al.
Publicado: (2018)

Antemortem CSF Aβ42/Aβ40 ratio predicts Alzheimer's disease pathology better than Aβ42 in rapidly progressive dementias
por: Baiardi, Simone, et al.
Publicado: (2018)

Dynamic Blood Concentrations of Aβ(1–40) and Aβ(1–42) in Alzheimer’s Disease
por: Yang, Yuan-Han, et al.
Publicado: (2020)

Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40
por: Wisch, Julie K., et al.
Publicado: (2023)

Self-Assembly of Aβ40, Aβ42 and Aβ43 Peptides in Aqueous Mixtures of Fluorinated Alcohols
por: Pachahara, Sanjai Kumar, et al.
Publicado: (2015)

Differentiating Aβ40 and Aβ42 in amyloid plaques with a small molecule fluorescence probe
por: Yang, Jing, et al.
Publicado: (2020)

Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1–40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology
por: Michno, Wojciech, et al.
Publicado: (2019)

Enhanced Aβ(1–40) Production in Endothelial Cells Stimulated with Fibrillar Aβ(1–42)
por: Rajadas, Jayakumar, et al.
Publicado: (2013)

Cerebrospinal Fluid Aβ40 Improves the Interpretation of Aβ42 Concentration for Diagnosing Alzheimer’s Disease
por: Dorey, Aline, et al.
Publicado: (2015)

Varied Probability of Staying Collapsed/Extended at the Conformational Equilibrium of Monomeric Aβ(40) and Aβ(42)
por: Song, Wanling, et al.
Publicado: (2015)

The Position of Aβ(22−40) and Aβ(1−42) in Anionic Lipid Membranes Containing Cholesterol
por: Barrett, Matthew A., et al.
Publicado: (2015)

X-ray diffraction and electron microscopy data for amyloid formation of Aβ40 and Aβ42
por: Selivanova, Olga M., et al.
Publicado: (2016)

Presenilin 1 deficiency impairs Aβ42-to-Aβ40- and angiotensin-converting activities of ACE
por: Gao, Yuan, et al.
Publicado: (2023)

Amyloid β-peptides 1–40 and 1–42 form oligomers with mixed β-sheets
por: Baldassarre, Maurizio, et al.
Publicado: (2017)

The Aβ1–42/Aβ1–40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1–42 alone
por: Delaby, Constance, et al.
Publicado: (2022)

Cell Line Specific Modulation of Extracellular Aβ(42) by Hsp40
por: Carnini, Anna, et al.
Publicado: (2012)

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
por: Hansson, Oskar, et al.
Publicado: (2019)

Reduced Influence of apoE on Aβ43 Aggregation and Reduced Vascular Aβ43 Toxicity as Compared with Aβ40 and Aβ42
por: Jäkel, Lieke, et al.
Publicado: (2020)

Diagnostic Utility of Selected Serum Dementia Biomarkers: Amyloid β-40, Amyloid β-42, Tau Protein, and YKL-40: A Review
por: Wilczyńska, Karolina, et al.
Publicado: (2020)

Effects of Heart Bypass Surgery on Plasma Aβ40 and Aβ42 Levels in Infants and Young Children
por: Hu, Yaoqin, et al.
Publicado: (2016)

Multicenter Analytical Validation of Aβ40 Immunoassays
por: van Waalwijk van Doorn, Linda J. C., et al.
Publicado: (2017)

Low Cerebrospinal Fluid Aβ(42) and Aβ(40) are Related to White Matter Lesions in Cognitively Normal Elderly
por: Skoog, Ingmar, et al.
Publicado: (2018)

DNA Damage Increases Secreted Aβ(40) and Aβ(42) in Neuronal Progenitor Cells: Relevance to Alzheimer’s Disease
por: Welty, Starr, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n7ndbg7rusvpkq501hrp0bmtaa